PHARMACY

FDA approves first drug for Peyronie’s disease

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a sexual deformity that affects men.

The FDA announced the approval of Auxilium Pharmaceuticals’ Xiaflex (collagenase clostridium histolyticum), the first drug treatment for Peyronie’s disease. Peyronie’s disease results from a lump of scar tissue in the penis that causes a curvature of at least 30 degrees during erection, which can make sexual intercourse difficult. Xiaflex received FDA approval in 2010 for Dupuytren’s contractor, a progressive hand disease that can affect a person’s ability to straighten and properly use their fingers.

"Today’s approval expands the available treatment options for men experiencing Peyronie’s disease and enables them, in consultation with their doctor, to choose the most appropriate treatment option," FDA Division of Bone, Reproductive and Urologic Products deputy director Audrey Gassman said.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Taro to repurchase up to 5.3% of outstanding stock for $200 million

BY Alaric DeArment

HAWTHORNE, N.Y. — Taro Pharmaceutical Industries plans to repurchase up to $200 million of its own shares, the Israeli generic drug maker said.

Taro announced a tender offer to repurchase the shares for between $84.50 and $97.50 each, with the total amount representing 4.6% to 5.3% of its outstanding shares.

The offer expires on Dec. 23, the company said.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Teva launches imiquimod cream

BY Alaric DeArment

NORTH WALES, Pa. — Teva Pharmaceutical Industries’ U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

Teva Pharmaceuticals announced the launch and availability of imiquimod cream, a generic version of Medicis Pharmaceutical Corp.’s Aldara.

The drug is used to treat external genital and rectal warts, certain types of actinic keratosis and basal cell carcinoma. Various versions of the drug had sales of about $244 million in 2011, according to IMS Health.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES